🔒

testosteroneinwomen.com: Landing Page Concept

Enter the hub password to continue.

That's not right. Try again.

testosteroneinwomen.com: The Landing Page Concept

Drafted 2026-07-25. Revised the same evening after four decisions settled.

You own a domain that names a single subject exactly, which is the rare case where the URL itself is the search query. This is the plan for what goes on it. The first draft treated the site as a front door feeding the paid SmartStrongAlive Substack. That model is gone: with SSA paused and its list empty, there's nothing to funnel into, so this domain is the primary home.

Your four decisions

Question	Answer	What it changes
Your name in the hero?	Yes	The site is first-person and signed. The hero carries a byline; the "who's writing this" section gets shorter, not longer.
Buy defensive domains?	No	Nothing gets registered. The competitive risk from the domain sweep is managed by shipping first rather than by buying names.
Spanish track?	No	Single-language URL structure. No /es/ prefix, no hreflang. Removes a whole build decision.
Do the live SSA articles have traffic?	No	This is the big one, and it changes the strategy rather than the page. Below.

What zero SmartStrongAlive traffic changes

Yesterday's plan rested on a claim that turns out to be false. It said the three live SmartStrongAlive articles "keep accruing search authority while you build here," and that this site would borrow that authority. With no traffic, there's no authority to borrow. I've pulled that reasoning out of the rest of the plan.

Two consequences. One of them you'll like.

The good one: the reason not to migrate has evaporated. The argument for leaving those articles on SmartStrongAlive was that moving them would cost accrued ranking. There's nothing to cost. No traffic, no subscribers, no list. Migrating them here with 301 redirects means this domain launches with four real, cited articles behind the landing page instead of a landing page with nothing behind it. A new site with substance ranks better and converts better than a new site without it. My recommendation is to migrate them. This reverses yesterday's call, and it reverses it because the fact underneath it changed.

The one you won't enjoy: this is information about the content, not just the domain. Zero traffic on three published, well-researched articles means publishing and waiting hasn't worked. Moving them to a better-named domain will help some, because an exact-match domain on an unclaimed namespace is a genuine advantage. It won't be sufficient on its own. If the site ships and nobody comes, the missing piece will be distribution, not writing. I'd rather decide now how people are going to find this than discover the same gap again in six months. That's a separate conversation from this page, and it's the one I'd want to have next.

Positioning

The site answers one question the medical system answers badly: should I be on testosterone, and if so, how do I actually get it? Every asset you have maps to part of that question. The three-part series covers what it does. The assay research covers why the labs mislead. The Colorado and Boulder research covers access. The regulatory work covers why it's hard. Nobody has assembled those four into one place, because nobody has the incentive to: there's no manufacturer selling a female-dosed product in the US, so there's no marketing budget behind the answer.

The scope now includes testosterone used alongside estrogen and progesterone, which is a stronger position than testosterone alone and is underserved. Most coverage treats testosterone as a bolt-on to HRT rather than as one leg of a three-hormone decision.

The hero line, now verified

Checked against the FDA's own database overnight, 2026-07-25.

I queried Drugs@FDA directly across the whole testosterone family: base, cypionate, enanthate, undecanoate, propionate and methyltestosterone. The note and the raw data are saved to ResearchLibrary at fda-orangebook-2026-07-testosterone-approved-products.

"Twelve" was wrong. It matches nothing in the database, so it's gone. The real numbers are 10 marketed brand-name products (AndroGel, Testim, Vogelxo, Natesto, Jatenzo, Kyzatrex, Tlando, Xyosted, Aveed, Azmiro), or 11 counting Testopel, which is a recognizable brand sitting on the generic pathway. Counting generics too, it's 68 marketed products. Zero carry a female indication. That half was always solid.

So the safe hero line, verified exactly as written:

Ten FDA-approved testosterone products. None of them for women.

But the query turned up something better

Combination estrogen-plus-testosterone injectables were FDA-approved in the US, and every one of them is discontinued: Depo-Testadiol (estradiol cypionate plus testosterone cypionate), Ditate-DS, and two more. That lands directly on your widened scope. The US once had approved products in exactly the category you're writing about, and then it didn't. Nobody replaced them.

The US once approved estrogen-plus-testosterone therapy for women. Every one of those products has been discontinued.

One check before that stronger line ships. Read the original Depo-Testadiol label and confirm the indication was menopausal. The composition makes it near-certain, but I retrieved approval records, not indication text, and "approved for women" is a claim that needs the label behind it rather than an inference. Until that's done, use the ten-products line.

One more thing the query settled. The esterified-estrogens-plus-methyltestosterone products (Covaryx, EEMT) are the obvious counter-example someone will raise against "none for women." They don't appear in Drugs@FDA as approved applications at all, which is consistent with unapproved-marketed-drug status. That's your answer if it comes up.

Page architecture

Seven sections, one primary action. No sticky anything. The header scrolls away.

1. Hero

Full-bleed photograph, a woman in her fifties, aspirational realism, not stock cheerfulness and not a clinical setting. Deep-color scrim over the lower third so white type stays legible. Headline is the approved-for-men fact in the display serif. One subhead sentence names what the site does. One CTA, and nothing else above the fold.

The byline is new, and it's your decision made visible. Your name sits directly under the subhead, small, in the sans. Identity first, receipts rather than adjectives:

Annette Thompson. Medical technologist. I read the primary research, and I'm on testosterone myself.

Three plain facts, no positioning language. The third is what separates this from a content farm, and it's yours to state without hedging. If you want a photograph of yourself on the page, it belongs here rather than further down.

2. The three doors

Three cards immediately under the hero, because these are the three things people actually arrive wanting.

Door	The question behind it
Do I need it?	Symptoms, and the honest answer that for some women it's no
Why are my labs "normal"?	The assay problem: standard immunoassays are unreliable at female concentrations
Who will prescribe it?	Access, off-label reality, what to ask for

Each card opens a real page, not an anchor link. This is the section that earns search traffic, and it's the one to build out first.

3. It was never only about libido

The differentiator, and the section worth the most craft. Testosterone gets filed under libido, so women who don't lead with a libido complaint never get offered it. The dopamine pathway, and anhedonia specifically, is where your material is strongest and where the whitespace analysis found a real gap. Lead with the flatness, not the mechanism. The mechanism follows briefly, with the study design named. Anhedonia gets defined in plain words the first time it appears.

4. Why the research missed it

Short, and the credibility spine of the whole site. Not a grievance piece: a methods piece. Trials that measured the wrong endpoint, doses drawn from male protocols, assays that can't resolve female ranges, and the twelve words that ended Intrinsa. This is where a skeptical reader decides whether the site is serious.

5. Who's writing this

Shorter now, because the hero byline already did the introduction. This section adds what the byline couldn't hold: decades of reading primary research, APOE4/E4, and why the subject stopped being academic for you. Medical humility stated once, without apology. You read the research and explain the study design, you're not prescribing, and every decision belongs with a clinician who knows the patient.

6. The email course

This is the section that changed most. With SSA paused and its list empty, the course builds a list here. Episode six no longer hands readers off anywhere; it invites them to stay for the ongoing work on this domain.

The six-part series is already fully architected in your research files, so the offer exists: why you weren't told, what it actually does, why the research missed it, why your labs lie, the side effects, how to actually get it. This is the only ask on the page, and it appears near the end, after the case is made. A quiet inline link at most before that point. That placement is your anti-AI voice rule, and it's also just correct, because nobody subscribes before they believe you.

Backend recommendation: capture to a Cloudflare Worker writing to D1, with the six-email drip sent on a scheduled Worker through Resend. You already run exactly that stack on the daily traffic report, it costs nothing at your volume, and the list stays yours rather than living inside someone else's platform. The honest tradeoff is that deliverability, double opt-in, unsubscribe handling and the CAN-SPAM footer become things we build and test rather than things a paid provider handles. That's roughly a day of work, and it's a day I'd spend, because a hosted provider at list-building scale is a recurring bill for features you need to get right only once.

Per your standing rule: the backend gets built, deployed and tested end to end before the page ships. No broken forms, ever.

7. Footer

Sources, the clinician line, and a link to SmartStrongAlive. If the articles migrate here, that link becomes a courtesy rather than a cross-sell.

Visual direction

Base: stark white or warm ivory. A light page, deliberately.
One deep section: "why the research missed it" reversed out in deep teal or burgundy with white type. One dark section, used once, so it lands.
Accent: a single warm accent, sunset orange or gold, on CTAs and rules only.
Type: editorial serif headlines, clean sans body, generous line height.
Imagery: aspirational realism. Real women in their fifties, natural light. No pill bottles, no syringes, no stethoscopes, no white coats. The subject is a life, not a treatment.
Structure: full-bleed section backgrounds, centered content container, grids that wrap at every width, zero horizontal overflow from 320 to 2560, and no sticky elements anywhere.

What to build, in order

The email backend. Worker, D1 table, Resend integration, the six-email sequence loaded, double opt-in working, unsubscribe working, tested end to end with a real address. First, not last, because the page can't ship without it.
The landing page, with capture wired to that backend.
The three door pages, since that's where search intent lands.
The article migration, if you approve it: the four articles move here with 301s from SmartStrongAlive.
The prescriber resource last, gated, and only after a redaction pass. It draws on personal-health source material and it goes stale fast.

Still open

Migrate the four SSA articles here, or leave them? I recommend migrating, for the reasons above. It's the only decision affecting build order, and it isn't blocking steps 1 through 3.
Distribution. Not a landing-page question, but the one that decides whether any of this gets read. Worth its own session once the site exists.
A photograph of you for the hero, if you want one there.

Landing page concept revised 2026-07-25 · annettethompson.com/hub